Medicenna Therapeutics Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Fahar Merchant
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2 Bloor Street West Toronto ON Canada M4W 3E2
- IPO Date
- Nov 13, 2017
- CIK
- 0001807983
- Website
- medicenna.com
- Similar Companies
- Business
- Medicenna Therapeutics Corp. operates as a clinical-stage immuno-oncology firm, diligently focused on the advancement and commercialization of its proprietary Superkines and advanced Empowered Cytokine technologies for addressing cancer and other significant medical conditions. Their leading therapeutic candidate, MDNA11, represents an ingeniously engineered, long-acting IL-2 super-agonist. This innovative molecule is specifically designed to preferentially stimulate the immune system's cancer-fighting cells, demonstrating promising anti-tumor efficacy across various challenging solid tumors, including pancreatic and melanoma, and is currently undergoing Phase 1/2 clinical evaluation. The company's pipeline also features bizaxofusp, previously known as MDNA55, an IL-4 receptor targeted therapy that has progressed through a Phase 2b clinical trial for recurrent glioblastoma, having also secured Fast-Track and Orphan Drug designations from regulatory authorities. Furthermore, Medicenna is developing MDNA209, an IL-2 Superkine antagonist aimed at treating autoimmune disorders such as multiple sclerosis and graft-versus-host disease. Additional candidates include MDNA413, a dual IL-4/IL-13 antagonist for cancer immunotherapies, and MDNA132, an IL-13 Superkine targeting diverse solid tumors by binding to receptors often overexpressed on cancerous cells. Complementing these individual assets, Medicenna employs its adaptable BiSKITs platform, enabling the creation of bifunctional Superkine Immunotherapies, such as MDNA113, which are designed to combine multiple synergistic therapeutic actions within a single molecular construct, offering enhanced strategies against challenging malignancies. The corporation maintains its central operations in Toronto, Canada.
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
Medicenna Announces the Launch of a Marketed Public Offering of Securities
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Medicenna Therapeutics Announces Participation in Upcoming Conferences
Medicenna Announces Changes to Board Composition
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Clinical Data From ABILITY-1 Study Evaluating MDNA11 in Cancer Immunotherapy Transcript
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
Medicenna Therapeutics Announces Participation in Upcoming Conferences
Medicenna Announces Results of Annual Meeting of Shareholders
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)